查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1866675

外泌体：全球市场份额和排名、总收入和需求预测（2025-2031年）

Exosomes - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 103 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球外泌体市场预计在 2024 年达到 6.28 亿美元，预计到 2031 年将达到 17.28 亿美元，2025 年至 2031 年的复合年增长率为 15.3%。

外泌体是直径约30-150奈米的奈米级细胞外囊泡，在生理和病理条件下由多种细胞类型透过胞吐作用分泌。它们存在于血液、尿液和脑脊髓液等生物体液中，并携带多种生物分子，包括蛋白质、脂质、DNA、mRNA和miRNA。外泌体在细胞间通讯、免疫调节、肿瘤进展、组织修復和神经退化性疾病路径中发挥重要作用。奈米级分离技术、生物标记鑑定和高通量体学研究的进步，使外泌体成为液态生物检体和早期疾病诊断的强大工具，以及靶向药物递送、免疫调节疗法和再生医学的潜在载体。目前，外泌体正从研究应用转向商业临床产品和新药开发，作为精准医疗、细胞疗法和RNA疗法的关键组成部分，引起了监管机构和全球投资者的广泛关注。

受精准医疗需求激增、液态生物检体和早期诊断技术突破以及RNA药物递送平台商业化等因素的推动，外泌体产业正经历快速扩张。多家大型製药和生物技术公司报告称，已将外泌体纳入其肿瘤、免疫和神经退化性疾病的研发管线，多个候选药物已进入临床试验阶段。资本投资依然强劲，主要的合约研发生产机构（CDMO）正在加速开发外泌体生产流程和符合GMP标准的设施。政府对再生医学和先进治疗方法的支持进一步促进了外泌体从研究阶段转向商业化生产的转变。凭藉其天然的递送能力和低免疫抗原性，外泌体正成为细胞和核酸疗法的重要补充，展现出巨大的市场潜力。

儘管外泌体领域具有巨大的成长潜力，但仍面临许多挑战，包括技术门槛高、缺乏标准化通讯协定以及商业模式尚不成熟。目前的分离纯化技术成本高且产量低，阻碍了规模化生产。全球法规结构分散，品管、临床认证和安全评估要求差异显着，减缓了外泌体的商业化进程和全球市场扩张。此外，激烈的智慧财产权竞争也提高了进入门槛，尤其对中小企业而言更是如此。投资者对临床进展和商业化策略的谨慎态度也造成了不确定性，凸显了持续创新和可扩展生产解决方案的必要性。

下游应用正迅速从研究主导市场扩展到商业性临床服务和治疗产品领域。液态生物检体的发展强化了外泌体作为非侵入性诊断生物标记的作用，而其在药物递送和免疫调节方面的应用则提高了细胞和基因疗法的精准性和安全性。美容和抗衰老龄化市场也催生了对基于外泌体产品的新需求。人工智慧驱动的体学技术、自动化纯化平台和可扩展生物製程的进步，使得高通量、高灵敏度和工业规模的生产成为可能。随着精准医疗和RNA疗法的快速发展，预计未来五到十年内，外泌体将成为生物製药产业的主要创新驱动力。

本报告旨在对全球外泌体市场进行全面分析，重点关注总收入、市场份额和主要企业的排名，还包括按地区/国家、类型和应用对外泌体的分析。

本报告以销售收入为基准年（2024 年），对 2020 年至 2031 年期间的外泌体市场规模、估计值和预测进行了呈现，并包含了历史数据和预测数据。报告运用定量和定性分析，帮助读者制定外泌体业务/成长策略，评估竞争格局，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • CellResearch
  • ExoCoBio
  • Skinlabs Medical
  • Thermo Fisher Scientific
  • Qiagen
  • System Biosciences（SBI）
  • Merck
  • Norgen Biotek
  • StemCells21
  • Codiak Biosciences
  • Exosome Diagnostics
  • Evox Therapeutics
  • Aegle Therapeutics
  • Danaher
  • Lonza

按类型分類的细分市场

  • 科学研究成果
  • 美容与抗衰老
  • 治疗和诊断

应用领域

  • 瘤
  • 神经系统疾病
  • 再生医学
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Exosomes was estimated to be worth US$ 628 million in 2024 and is forecast to a readjusted size of US$ 1728 million by 2031 with a CAGR of 15.3% during the forecast period 2025-2031.

Exosomes are nanoscale extracellular vesicles with diameters of approximately 30-150 nanometers, secreted by various cell types through exocytosis under physiological or pathological conditions. Found in biological fluids such as blood, urine, and cerebrospinal fluid, they carry a wide range of biomolecules including proteins, lipids, DNA, mRNA, and miRNA, playing a key role in intercellular communication, immune regulation, tumor progression, tissue repair, and neurodegenerative disease pathways. Advances in nanoscale isolation technologies, biomarker identification, and high-throughput omics research have positioned exosomes as powerful tools for liquid biopsy and early disease diagnosis, as well as promising vectors for targeted drug delivery, immune modulation therapies, and regenerative medicine. Today, exosomes are transitioning from research applications to commercial clinical products and novel drug development, serving as a critical component of precision medicine, cell therapy, and RNA-based therapeutics, attracting significant attention from regulatory agencies and global investors.

The exosome industry is experiencing rapid expansion, driven by surging demand for precision medicine, breakthroughs in liquid biopsy and early diagnostic technologies, and the commercialization of RNA drug delivery platforms. According to reports from leading pharmaceutical and biotech companies, exosomes have been incorporated into oncology, immunology, and neurodegenerative disease pipelines, with several candidates advancing into clinical trials. Capital investment remains strong, and leading CDMO providers are accelerating the development of exosome manufacturing processes and GMP-compliant facilities. Government support for regenerative medicine and advanced therapies is further accelerating the transition of exosomes from research to commercial-scale production. With their natural delivery capabilities and low immunogenicity, exosomes are emerging as a key complement to cell and nucleic acid therapeutics, offering vast market potential.

Despite its high growth potential, the exosome sector faces substantial challenges, including high technical barriers, lack of standardized protocols, and an evolving commercial model. Current isolation and purification techniques remain costly and low-yield, hindering scalability. Global regulatory frameworks are fragmented, with significant variations in quality control, clinical certification, and safety evaluation requirements, slowing commercialization and global market expansion. Additionally, intense competition in intellectual property creates significant entry barriers, particularly for smaller firms. Investor caution over clinical progress and commercialization strategies also introduces uncertainty, emphasizing the need for continuous technological innovation and scalable manufacturing solutions.

Downstream applications are rapidly expanding from research-driven markets to commercial clinical services and therapeutic products. The growth of liquid biopsy is enhancing exosomes' role as a non-invasive diagnostic biomarker, while their use in drug delivery and immune modulation is improving the precision and safety of cell and gene therapies. The aesthetics and anti-aging markets are also creating new demand for exosome-based products. Advances in AI-driven omics, automated purification platforms, and scalable bioprocessing will enable high-throughput, high-sensitivity, and industrial-scale production. With the rapid growth of precision medicine and RNA therapeutics, exosomes are poised to become a major innovation driver in the biopharmaceutical industry over the next 5-10 years.

This report aims to provide a comprehensive presentation of the global market for Exosomes, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Exosomes by region & country, by Type, and by Application.

The Exosomes market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Exosomes.

Market Segmentation

By Company

  • CellResearch
  • ExoCoBio
  • Skinlabs Medical
  • Thermo Fisher Scientific
  • Qiagen
  • System Biosciences (SBI)
  • Merck
  • Norgen Biotek
  • StemCells21
  • Codiak Biosciences
  • Exosome Diagnostics
  • Evox Therapeutics
  • Aegle Therapeutics
  • Danaher
  • Lonza

Segment by Type

  • Scientific Research Products
  • Beauty and Anti-aging
  • Treatment and Diagnosis

Segment by Application

  • Tumors
  • Neurological Diseases
  • Regenerative Medicine
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Exosomes company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Exosomes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Exosomes in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Exosomes Product Introduction
  • 1.2 Global Exosomes Market Size Forecast (2020-2031)
  • 1.3 Exosomes Market Trends & Drivers
    • 1.3.1 Exosomes Industry Trends
    • 1.3.2 Exosomes Market Drivers & Opportunity
    • 1.3.3 Exosomes Market Challenges
    • 1.3.4 Exosomes Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Exosomes Players Revenue Ranking (2024)
  • 2.2 Global Exosomes Revenue by Company (2020-2025)
  • 2.3 Key Companies Exosomes Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Exosomes Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Exosomes
  • 2.6 Exosomes Market Competitive Analysis
    • 2.6.1 Exosomes Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Exosomes Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Exosomes as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Scientific Research Products
    • 3.1.2 Beauty and Anti-aging
    • 3.1.3 Treatment and Diagnosis
  • 3.2 Global Exosomes Sales Value by Type
    • 3.2.1 Global Exosomes Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Exosomes Sales Value, by Type (2020-2031)
    • 3.2.3 Global Exosomes Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Tumors
    • 4.1.2 Neurological Diseases
    • 4.1.3 Regenerative Medicine
    • 4.1.4 Other
  • 4.2 Global Exosomes Sales Value by Application
    • 4.2.1 Global Exosomes Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Exosomes Sales Value, by Application (2020-2031)
    • 4.2.3 Global Exosomes Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Exosomes Sales Value by Region
    • 5.1.1 Global Exosomes Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Exosomes Sales Value by Region (2020-2025)
    • 5.1.3 Global Exosomes Sales Value by Region (2026-2031)
    • 5.1.4 Global Exosomes Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Exosomes Sales Value, 2020-2031
    • 5.2.2 North America Exosomes Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Exosomes Sales Value, 2020-2031
    • 5.3.2 Europe Exosomes Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Exosomes Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Exosomes Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Exosomes Sales Value, 2020-2031
    • 5.5.2 South America Exosomes Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Exosomes Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Exosomes Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Exosomes Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Exosomes Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Exosomes Sales Value, 2020-2031
    • 6.3.2 United States Exosomes Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Exosomes Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Exosomes Sales Value, 2020-2031
    • 6.4.2 Europe Exosomes Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Exosomes Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Exosomes Sales Value, 2020-2031
    • 6.5.2 China Exosomes Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Exosomes Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Exosomes Sales Value, 2020-2031
    • 6.6.2 Japan Exosomes Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Exosomes Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Exosomes Sales Value, 2020-2031
    • 6.7.2 South Korea Exosomes Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Exosomes Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Exosomes Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Exosomes Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Exosomes Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Exosomes Sales Value, 2020-2031
    • 6.9.2 India Exosomes Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Exosomes Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 CellResearch
    • 7.1.1 CellResearch Profile
    • 7.1.2 CellResearch Main Business
    • 7.1.3 CellResearch Exosomes Products, Services and Solutions
    • 7.1.4 CellResearch Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.1.5 CellResearch Recent Developments
  • 7.2 ExoCoBio
    • 7.2.1 ExoCoBio Profile
    • 7.2.2 ExoCoBio Main Business
    • 7.2.3 ExoCoBio Exosomes Products, Services and Solutions
    • 7.2.4 ExoCoBio Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.2.5 ExoCoBio Recent Developments
  • 7.3 Skinlabs Medical
    • 7.3.1 Skinlabs Medical Profile
    • 7.3.2 Skinlabs Medical Main Business
    • 7.3.3 Skinlabs Medical Exosomes Products, Services and Solutions
    • 7.3.4 Skinlabs Medical Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Skinlabs Medical Recent Developments
  • 7.4 Thermo Fisher Scientific
    • 7.4.1 Thermo Fisher Scientific Profile
    • 7.4.2 Thermo Fisher Scientific Main Business
    • 7.4.3 Thermo Fisher Scientific Exosomes Products, Services and Solutions
    • 7.4.4 Thermo Fisher Scientific Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Thermo Fisher Scientific Recent Developments
  • 7.5 Qiagen
    • 7.5.1 Qiagen Profile
    • 7.5.2 Qiagen Main Business
    • 7.5.3 Qiagen Exosomes Products, Services and Solutions
    • 7.5.4 Qiagen Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Qiagen Recent Developments
  • 7.6 System Biosciences (SBI)
    • 7.6.1 System Biosciences (SBI) Profile
    • 7.6.2 System Biosciences (SBI) Main Business
    • 7.6.3 System Biosciences (SBI) Exosomes Products, Services and Solutions
    • 7.6.4 System Biosciences (SBI) Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.6.5 System Biosciences (SBI) Recent Developments
  • 7.7 Merck
    • 7.7.1 Merck Profile
    • 7.7.2 Merck Main Business
    • 7.7.3 Merck Exosomes Products, Services and Solutions
    • 7.7.4 Merck Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Merck Recent Developments
  • 7.8 Norgen Biotek
    • 7.8.1 Norgen Biotek Profile
    • 7.8.2 Norgen Biotek Main Business
    • 7.8.3 Norgen Biotek Exosomes Products, Services and Solutions
    • 7.8.4 Norgen Biotek Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Norgen Biotek Recent Developments
  • 7.9 StemCells21
    • 7.9.1 StemCells21 Profile
    • 7.9.2 StemCells21 Main Business
    • 7.9.3 StemCells21 Exosomes Products, Services and Solutions
    • 7.9.4 StemCells21 Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.9.5 StemCells21 Recent Developments
  • 7.10 Codiak Biosciences
    • 7.10.1 Codiak Biosciences Profile
    • 7.10.2 Codiak Biosciences Main Business
    • 7.10.3 Codiak Biosciences Exosomes Products, Services and Solutions
    • 7.10.4 Codiak Biosciences Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Codiak Biosciences Recent Developments
  • 7.11 Exosome Diagnostics
    • 7.11.1 Exosome Diagnostics Profile
    • 7.11.2 Exosome Diagnostics Main Business
    • 7.11.3 Exosome Diagnostics Exosomes Products, Services and Solutions
    • 7.11.4 Exosome Diagnostics Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Exosome Diagnostics Recent Developments
  • 7.12 Evox Therapeutics
    • 7.12.1 Evox Therapeutics Profile
    • 7.12.2 Evox Therapeutics Main Business
    • 7.12.3 Evox Therapeutics Exosomes Products, Services and Solutions
    • 7.12.4 Evox Therapeutics Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Evox Therapeutics Recent Developments
  • 7.13 Aegle Therapeutics
    • 7.13.1 Aegle Therapeutics Profile
    • 7.13.2 Aegle Therapeutics Main Business
    • 7.13.3 Aegle Therapeutics Exosomes Products, Services and Solutions
    • 7.13.4 Aegle Therapeutics Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Aegle Therapeutics Recent Developments
  • 7.14 Danaher
    • 7.14.1 Danaher Profile
    • 7.14.2 Danaher Main Business
    • 7.14.3 Danaher Exosomes Products, Services and Solutions
    • 7.14.4 Danaher Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Danaher Recent Developments
  • 7.15 Lonza
    • 7.15.1 Lonza Profile
    • 7.15.2 Lonza Main Business
    • 7.15.3 Lonza Exosomes Products, Services and Solutions
    • 7.15.4 Lonza Exosomes Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Lonza Recent Developments

8 Industry Chain Analysis

  • 8.1 Exosomes Industrial Chain
  • 8.2 Exosomes Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Exosomes Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Exosomes Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Exosomes Market Trends
  • Table 2. Exosomes Market Drivers & Opportunity
  • Table 3. Exosomes Market Challenges
  • Table 4. Exosomes Market Restraints
  • Table 5. Global Exosomes Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Exosomes Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Exosomes Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Exosomes Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Exosomes
  • Table 10. Global Exosomes Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Exosomes as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Exosomes Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Exosomes Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Exosomes Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Exosomes Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Exosomes Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Exosomes Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Exosomes Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Exosomes Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Exosomes Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Exosomes Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Exosomes Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Exosomes Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Exosomes Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Exosomes Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Exosomes Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Exosomes Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Exosomes Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Exosomes Sales Value, (2026-2031) & (US$ Million)
  • Table 31. CellResearch Basic Information List
  • Table 32. CellResearch Description and Business Overview
  • Table 33. CellResearch Exosomes Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Exosomes Business of CellResearch (2020-2025)
  • Table 35. CellResearch Recent Developments
  • Table 36. ExoCoBio Basic Information List
  • Table 37. ExoCoBio Description and Business Overview
  • Table 38. ExoCoBio Exosomes Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Exosomes Business of ExoCoBio (2020-2025)
  • Table 40. ExoCoBio Recent Developments
  • Table 41. Skinlabs Medical Basic Information List
  • Table 42. Skinlabs Medical Description and Business Overview
  • Table 43. Skinlabs Medical Exosomes Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Exosomes Business of Skinlabs Medical (2020-2025)
  • Table 45. Skinlabs Medical Recent Developments
  • Table 46. Thermo Fisher Scientific Basic Information List
  • Table 47. Thermo Fisher Scientific Description and Business Overview
  • Table 48. Thermo Fisher Scientific Exosomes Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Exosomes Business of Thermo Fisher Scientific (2020-2025)
  • Table 50. Thermo Fisher Scientific Recent Developments
  • Table 51. Qiagen Basic Information List
  • Table 52. Qiagen Description and Business Overview
  • Table 53. Qiagen Exosomes Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Exosomes Business of Qiagen (2020-2025)
  • Table 55. Qiagen Recent Developments
  • Table 56. System Biosciences (SBI) Basic Information List
  • Table 57. System Biosciences (SBI) Description and Business Overview
  • Table 58. System Biosciences (SBI) Exosomes Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Exosomes Business of System Biosciences (SBI) (2020-2025)
  • Table 60. System Biosciences (SBI) Recent Developments
  • Table 61. Merck Basic Information List
  • Table 62. Merck Description and Business Overview
  • Table 63. Merck Exosomes Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Exosomes Business of Merck (2020-2025)
  • Table 65. Merck Recent Developments
  • Table 66. Norgen Biotek Basic Information List
  • Table 67. Norgen Biotek Description and Business Overview
  • Table 68. Norgen Biotek Exosomes Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Exosomes Business of Norgen Biotek (2020-2025)
  • Table 70. Norgen Biotek Recent Developments
  • Table 71. StemCells21 Basic Information List
  • Table 72. StemCells21 Description and Business Overview
  • Table 73. StemCells21 Exosomes Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Exosomes Business of StemCells21 (2020-2025)
  • Table 75. StemCells21 Recent Developments
  • Table 76. Codiak Biosciences Basic Information List
  • Table 77. Codiak Biosciences Description and Business Overview
  • Table 78. Codiak Biosciences Exosomes Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Exosomes Business of Codiak Biosciences (2020-2025)
  • Table 80. Codiak Biosciences Recent Developments
  • Table 81. Exosome Diagnostics Basic Information List
  • Table 82. Exosome Diagnostics Description and Business Overview
  • Table 83. Exosome Diagnostics Exosomes Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Exosomes Business of Exosome Diagnostics (2020-2025)
  • Table 85. Exosome Diagnostics Recent Developments
  • Table 86. Evox Therapeutics Basic Information List
  • Table 87. Evox Therapeutics Description and Business Overview
  • Table 88. Evox Therapeutics Exosomes Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Exosomes Business of Evox Therapeutics (2020-2025)
  • Table 90. Evox Therapeutics Recent Developments
  • Table 91. Aegle Therapeutics Basic Information List
  • Table 92. Aegle Therapeutics Description and Business Overview
  • Table 93. Aegle Therapeutics Exosomes Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Exosomes Business of Aegle Therapeutics (2020-2025)
  • Table 95. Aegle Therapeutics Recent Developments
  • Table 96. Danaher Basic Information List
  • Table 97. Danaher Description and Business Overview
  • Table 98. Danaher Exosomes Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Exosomes Business of Danaher (2020-2025)
  • Table 100. Danaher Recent Developments
  • Table 101. Lonza Basic Information List
  • Table 102. Lonza Description and Business Overview
  • Table 103. Lonza Exosomes Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Exosomes Business of Lonza (2020-2025)
  • Table 105. Lonza Recent Developments
  • Table 106. Key Raw Materials Lists
  • Table 107. Raw Materials Key Suppliers Lists
  • Table 108. Exosomes Downstream Customers
  • Table 109. Exosomes Distributors List
  • Table 110. Research Programs/Design for This Report
  • Table 111. Key Data Information from Secondary Sources
  • Table 112. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Exosomes Product Picture
  • Figure 2. Global Exosomes Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Exosomes Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Exosomes Report Years Considered
  • Figure 5. Global Exosomes Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Exosomes Revenue in 2024
  • Figure 7. Exosomes Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Scientific Research Products Picture
  • Figure 9. Beauty and Anti-aging Picture
  • Figure 10. Treatment and Diagnosis Picture
  • Figure 11. Global Exosomes Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Exosomes Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Tumors
  • Figure 14. Product Picture of Neurological Diseases
  • Figure 15. Product Picture of Regenerative Medicine
  • Figure 16. Product Picture of Other
  • Figure 17. Global Exosomes Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Exosomes Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Exosomes Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Exosomes Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Exosomes Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Exosomes Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Exosomes Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Exosomes Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Exosomes Sales Value (%), (2020-2031)
  • Figure 30. United States Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Exosomes Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Exosomes Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Exosomes Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Exosomes Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Exosomes Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Exosomes Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Exosomes Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Exosomes Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Exosomes Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Exosomes Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Exosomes Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Exosomes Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Exosomes Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Exosomes Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Exosomes Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Exosomes Industrial Chain
  • Figure 52. Exosomes Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed